Fate Therapeutics Inc/ US31189P1021 /
6/13/2024 10:00:00 PM | Chg. -0.0100 | Volume | Bid10:01:00 PM | Ask10:01:00 PM | High | Low |
---|---|---|---|---|---|---|
3.7600USD | -0.27% | 926,760 Turnover: 2.62 mill. |
3.7000Bid Size: 200 | 3.9000Ask Size: 500 | 3.9400 | 3.7300 |
GlobeNewswire
6/4
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
5/9
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
5/9
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-she...
GlobeNewswire
5/6
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Oper...
GlobeNewswire
5/3
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-b...
GlobeNewswire
4/22
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmu...
GlobeNewswire
4/2
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
3/19
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Pla...
GlobeNewswire
3/5
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2/26
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
GlobeNewswire
2/15
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial R...
Newsfile Corp
2/15
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
GlobeNewswire
2/2
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
1/8
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients wi...
GlobeNewswire
12/13/2023
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
11/8/2023
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
GlobeNewswire
11/4/2023
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Beh...
GlobeNewswire
11/2/2023
SHAREHOLDER ALERT: Morris Kandinov Investigating ARDX, LESL, ENVX, and FATE; Shareholders are Encour...
GlobeNewswire
10/25/2023
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results